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A patient decision aid for antidepressant
use in pregnancy: study protocol for a
randomized controlled trial
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Abstract
Background: Many women with depression experience significant difficulty making a decision about whether or
not to use antidepressant medication in pregnancy. Patient decision aids (PDAs) are tools that assist patients in
making complex health decisions. PDAs can reduce decision-making difficulty and lead to better treatment
outcomes. We describe the methods for a pilot randomized controlled trial of an interactive web-based PDA for
women who are having difficulty deciding about antidepressant drug use in pregnancy.
Methods/Design: This is a pilot randomized controlled trial that aims to assess the feasibility of a larger, multi-
center efficacy study. The PDA aims to help a woman: (1) understand why an antidepressant is being
recommended, (2) be knowledgeable about potential benefits and risks of treatment and non-treatment with
antidepressants, and (3) be clear about which benefits and risks are most important to her, with the goal of
improving confidence in her decision-making. We include women aged 18 years or older who are: (1) planning a
pregnancy or are pregnant (gestational age less than 30 weeks), (2) diagnosed with major depressive disorder, (3)
deciding whether or not to use a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake
inhibitor (SNRI) antidepressant in pregnancy, and (4) having at least moderate decision-making difficulty as per a
Decisional Conflict Scale (DCS) Score ≥25. Participants are randomized to receive the PDA or an informational
resource sheet via a secure website, and have access to the stated allocation until their final study follow-up. The
primary outcomes of the pilot study are feasibility of recruitment and retention, acceptability of the intervention,
and adherence to the trial protocol. The primary efficacy outcome is DCS score at 4 weeks post randomization, with
secondary outcomes including depressive and anxiety symptoms.
Discussion: Our PDA represents a key opportunity to optimize the decision-making process for women around
antidepressants in pregnancy, leading to effective decision-making and optimizing improved maternal and child
outcomes related to depression in pregnancy. The electronic nature of the PDA will facilitate keeping it up-to-date,
and allow for widespread dissemination after efficacy is demonstrated.
Trial registration: This trial is registered on ClinicalTrials.Gov under the identifier NCT02308592 (first registered: 2
December 2014).
Keywords: Depression, Pregnancy, Women, Patient decision aid, Randomized control trial
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Background
Depression complicates about 10 % of pregnancies
around the world [1, 2]. Some women present with a
relapse of pre-existing depression and others present
with new onset of illness. Untreated or incompletely
treated, depression has serious short- and long-term
impact on maternal health and exposed children [3, 4].
Depression in pregnancy affects the health and quality
of life of the woman, and untreated is associated with
increased risk for postpartum depression and chronic
maternal depression, conditions linked to impaired
mother-infant interactions and poor developmental and
emotional outcomes in the offspring [5–12]. Children
exposed to depression in utero are at risk for preterm
birth, lower birth weight, small head circumference,
and lower Apgar scores [3, 4]. Exposure to depression
in utero is also associated with childhood problems that
extend past the neonatal phase such as delayed infant
speech perception [13]. Unfortunately, although depres-
sion is one of the most common morbidities in preg-
nancy, as few as 20 % of women receive treatment [4].
Due to the negative consequences of depression in preg-
nancy, there is urgency to ensure effective treatment.
There are two standard types of treatment for depres-
sion in pregnancy. Psychotherapy is indicated as acute
therapy for depression of mild, and sometimes moderate,
severity in pregnancy, but psychotherapy alone is un-
likely to be effective if a woman has severe depression
[14]. Even when psychotherapy is effective, it may take
several weeks to months for symptoms to improve, leav-
ing the mother and fetus exposed to the effects of
untreated depression during that time. First-line anti-
depressant medications such as selective serotonin re-
uptake inhibitors (SSRIs), or serotonin-norepinephrine
reuptake inhibitors (SNRIs) are effective for treatment of
depression and prevention of relapse [14–20]. Approxi-
mately 67 % of individuals achieve remission using anti-
depressant medication [21]. In addition, as many as 68 %
of women who discontinue antidepressant use during
pregnancy suffer relapse, leaving themselves and their
infants susceptible to the effects of untreated depression
[22]. However, the use of antidepressant medication in
pregnancy must be considered in the context of the
safety of antidepressants for mother and fetus. This is a
complex decision because no treatment option is with-
out risk. While depression itself may increase risk for
adverse maternal and child outcomes, exposure to anti-
depressant medication in utero has been associated with
small increased risks of neonatal cardiovascular malfor-
mations, and neonatal pulmonary hypertension [23–25].
Spontaneous abortions, low birth weight and preterm
birth have also been reported in exposed infants, al-
though there is controversy as to whether these risks are
higher than among women with untreated depression
[26, 27]. Transient short-term adverse neuro-behavioural
neonatal effects have been more consistently reported,
but only in very rare cases (i.e., less than 1 in 1000)
have they been associated with serious effects such as
seizures [28–40]. Long-term effects of in-utero expos-
ure are difficult to disentangle from effects of genetics
and maternal mood but these drugs cross the placenta
and the fetal blood-brain-barrier, suggesting that long-
term impact is possible [41, 42]. Many women have sig-
nificant difficulty making a decision about whether or
not to use antidepressant medication in pregnancy. In
our previous research, more than 50 % of women faced
with this decision displayed high levels of decision con-
flict, a construct associated with delayed, and ineffective
treatment decisions [43, 44]. This supports other re-
search indicating that women report that the complex-
ity of this decision is a barrier to overall treatment
uptake for depression in pregnancy [45].
Patient decision aids (PDAs) are evidence-based tools de-
signed to help people engage in choices among options by
providing information on the options and outcomes rele-
vant to health status [46]. PDAs are used to supplement,
not replace, consultation between health care professionals
and patients and aim to prepare individuals to make com-
plex health decisions such as this one where no treatment
decision is without risk [47–51]. A Cochrane Collaboration
systematic review and meta-analysis of 115 studies demon-
strated that patients who use PDAs have better knowledge
of their options and more realistic expectations of possible
outcomes [47]; and that PDAs can be effective at reducing
decisional conflict. We developed a web-based interactive
PDA to help women who are pregnant or planning a preg-
nancy and who are deciding whether or not to use an anti-
depressant to treat depression. The PDA was developed by
a team of perinatal psychiatry experts in Ontario, Canada,
in collaboration with front-line perinatal mental health pro-
viders, PDA experts and a health care technology company,
QoC Health. Herein we present the methodology of a pilot
randomized controlled trial (RCT) that evaluates the feasi-
bility of a trial protocol to evaluate the efficacy of our PDA
(Research Protocol Version 8; 24 November 2015). The
primary objective of the current protocol is to assess feasi-
bility, acceptability and adherence with a prospective, two-
armed pilot RCT protocol to evaluate the efficacy of the
PDA for women making decisions about the treatment of
their depression with an antidepressant during pregnancy.
This will guide the development of a larger RCT to defini-
tively evaluate the efficacy of the PDA.
Methods/Design
Study design, setting and recruitment
This is a two-armed, pilot RCT enrolling women with
depression who are pregnant or planning a pregnancy
and are having difficulty deciding whether or not they
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should start or continue an SSRI or SNRI antidepressant
for treatment of depression in pregnancy (this is shown
in detail in Fig. 1, see Additional file 1). Participants are
being recruited over 1 year from a specialty perinatal
mental health program at Women’s College Hospital
(WCH) in Toronto, Ontario, Canada (population ap-
proximately 3.5 million) that receives referrals for men-
tal health care of women during pregnancy from all over
the Greater Toronto Area, and the associated family
practice program at WCH. Psychiatrists or family physi-
cians at WCH can refer patients directly to the study.
To encourage recruitment, referring providers including
psychiatrists, family physicians, obstetricians and mid-
wives have been informed of the study; and it has been
advertised on WCH social media platforms. The website
for the PDA is maintained by a specialty information
technology (IT) vendor, QoC Health.
After providing informed consent to the study, partici-
pants are assigned a participant identification (ID), affili-
ated with a randomization allocation, in sequence by a
research coordinator who is blind to the allocation.
Randomization is stratified by study site (i.e., psychiatry
or family practice). A unique website log-in is generated
for each woman such that she will be presented with her
allocated condition upon log-in. The research coordin-
ator administers a baseline questionnaire and each
woman is given her unique website log-in information.
Follow-up questionnaires for outcome data are adminis-
tered at 4 weeks after the baseline assessment for collec-
tion of primary outcome data; and again for long-term
follow-up at 12 weeks postpartum (for women who en-
rolled while pregnant) or 6 months after baseline (for
women who enrolled while planning a pregnancy). All
questionnaires for the study are conducted either by
phone or in person, depending on the participant’s pref-
erence. Outcome data collectors are blind to study group
allocation during the baseline assessment and the
follow-up questionnaire. Treating physicians are not dir-
ectly told of participant allocation, but participants are
free and encouraged to discuss it with them. The Re-
search Ethics Board (REB) of WCH in Toronto, Ontario,
Canada approved the study (REB# 2014-0050-B) and is
notified when changes are made to the study protocol.
The study is registered with ClinicalTrials.Gov under the
identifier NCT02308592; the trial registration is also up-
dated as appropriate.
Eligibility criteria
Included participants are: (1) female, (2) aged 18 years
or older, (3) planning a pregnancy or less than 30 weeks
gestation at enrollment, (4) considering starting or con-
tinuing SSRI or SNRI antidepressant medication in preg-
nancy for major depressive disorder, and (5) have
moderate-to-high decision-making difficulty, as defined
by a score of ≥25 on the Decisional Conflict Scale [51].
Participants are excluded from the study if they have: (1)
had alcohol and/or substance use or dependence in the
previous 6 months, (2) active suicidal ideation or psych-
osis, (3) any major obstetrical complications or fetal
cardiac anomalies diagnosed in the current or a past
pregnancy (as this changes the risk/benefit ratio discus-
sion in regards to antidepressant use), (4) an inability to
read, speak, or understand English and do not have
Fig. 1 Trial scheme for a pilot randomized control trial for a patient decision aid (PDA) for antidepressant use in pregnancy
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someone that can read the PDA to them, or (5) are
otherwise incapable of consenting to participation.
Informed consent procedures
Potentially eligible women who are willing to hear more
about the study receive a detailed study explanation
from the study research coordinator. Subjects are pro-
vided with a clear explanation of the objectives, proce-
dures, risks and benefits of the study and all questions
are answered. Questions are asked of subjects to ensure
that they understand the nature of the research, risks
and potential benefits of study participation, and their
rights as research subjects prior to signing the informed
consent document. Interested patients are asked to sign
the informed consent form before entry into the study.
Informed consent is obtained before any study assess-
ments are performed and before any private information
is recorded. Participants are given meaningful opportun-
ities during the study to provide ongoing consent to
continuation with the study protocol.
Allocation of interventions
After informed consent procedures, eligible and consent-
ing women are given a sequential study ID number that
is affiliated with a unique username and password for
the study website. These ID numbers have been ran-
domized to affiliation with either the intervention or a
control condition and are distributed in sequence by a
research coordinator who is blind to the allocation. Par-
ticipants are randomized in a 1:1 ratio with stratification
by whether their treating clinician is a psychiatrist or a
family physician. When logging into the website using
their unique log-in information, participants will see ei-
ther the PDA or the control condition, a resource sheet
with information on depression and antidepressant use
in pregnancy.
Interventions
The PDA is an interactive website that aims to help
women: (1) understand why SSRI/SNRI antidepressant
medication is being recommended, (2) be knowledgeable
about the potential benefits and risks of treatment with
antidepressant medication in pregnancy as well as the
benefits and risks of not using antidepressant medica-
tion, and (3) be clear about which benefits and risks are
most important to her, with the goal of improving confi-
dence in her decision-making. To achieve these aims,
the PDA intervention has three main sections: (1)
evidence-based information about depression in preg-
nancy and each treatment option and procedure, (2)
evidence-based information on the risks and benefits of
both untreated depression and antidepressant treatment,
integrated with a series of exercises, called “values clari-
fication methods” to help women determine which risks
and benefits are most important to them. In keeping
with research on the decisional needs of women regard-
ing antidepressant use in pregnancy, it includes explicit
exercises to help women consider how their relation-
ships with partners, family, friends, community and pro-
viders impact the decision-making process, and (3) a
summary section that outlines the information reviewed
and which benefits and risks they deemed most import-
ant. At the end of the module, participants will see this
summary sheet as a printable PDF which can be printed
to take with them to their treating clinician for use in
clinical follow-up. Women can review the PDA alone or
with others if desired (e.g., partner, family, friends).
However, the electronic nature of the decision-support
tool with secure password also ensures that women can
work privately with the PDA. This format also allows
women unlimited log-ins so they can complete the PDA
at their leisure (or re-read sections/repeat exercises as
many times as desired). The intent is to create flexibility
in the face of competing demands such as work or child-
care. The intervention is written at a grade 6 literacy
level and takes approximately 20 minutes to complete. It
is best viewed on a desktop or laptop computer. The last
page of the PDA is a resource sheet, formatted as a
printable PDF with references to standard published in-
formation and resources for antidepressant use in preg-
nancy. Participants who have been allocated the control
condition will receive only the resource sheet.
Study schedule
The study schedule is described in Table 1. A baseline
assessment with the research coordinator occurs either
in person or by phone, prior to the participant receiving
her log-in information for the website. After the baseline
assessment, each participant receives her log-in informa-
tion. Two follow-up questionnaires are then completed
in person or by telephone (depending on patient prefer-
ence): (1) 4 weeks later, and (2) at 12 weeks postpartum
for women who enrolled while pregnant, or 6 months
post randomization for women who enrolled while plan-
ning pregnancy.
Outcomes
The primary outcomes for the pilot study are feasibility,
acceptability, and adherence with the trial protocol.
Feasibility describes how well the trial protocol can be
implemented. We record feasibility data related to: (1)
eligibility (e.g., the rate of eligible women in each prac-
tice), (2) recruitment (e.g., recruitment rate and reasons
for non-participation), and (3) timing (e.g., average time
from study enrollment to participant use of the PDA).
Acceptability refers to women’s satisfaction with and
perceptions of the PDA. We record acceptability data
on: (1) the participants’ views of the PDA, (2) the rate of
Vigod et al. Trials  (2016) 17:110 Page 4 of 9
completion of the PDA and reasons for discontinuation
(e.g., the number of women who view all pages of the
PDA), and (3) measures related to participant PDA use
(e.g., the length of time it takes to complete the PDA,
the number of log-ins required to complete the PDA,
average number of times the PDA is completed, and the
average number of PDA page views, rate of use of PDA
summary sheet in clinical follow-up), and (4) clinical
providers’ views of the PDA. Lastly, we assess adherence,
defined as the degree to which the trial protocol is
followed. Adherence-related measures include: (1) the
number of women who see their clinical provider for
follow-up within 4 weeks of enrolling in the study, and
(2) the follow-up rate for data collection.
Secondary outcomes for the pilot study are the efficacy
of the PDA as an adjunct to clinical care on decisional
conflict (primary outcome for the future efficacy RCT),
psychiatric symptoms, and knowledge about depression
and antidepressant use in pregnancy. Provider views are
also collected. Decisional conflict is measured using the
Decisional Conflict Scale (DCS). The purpose of this scale
is to measure a person’s perception of difficulty in making
a decision including: (1) uncertainty in choosing between
options, (2) modifiable factors contributing to uncertainty
such as feeling uninformed, being unclear about personal
values, and unsupported, and (3) quality of the choice se-
lected, which is defined as informed and consistent with
personal values, and with which a person expresses per-
sonal satisfaction [43]. The DCS consists of 16 items (ran-
ging from 1 to 5, with 5 being high decisional conflict).
Scores of 25 or greater are associated with those who
delay decisions. Test-retest and internal consistency coef-
ficients exceed 0.78. Depressive and anxious symptoms
are measured using the Edinburgh Postnatal Depression
Scale (EPDS) and the State-Trait Anxiety Inventory
(STAI) respectively. The EPDS is a self-report depression
screening measure that has been validated for use in preg-
nancy [52]. The EPDS has a positive predictive value of 73
% at a cut-off score of 12/13 [53]. The STAI is a self-
report screening measure for anxiety that has shown good
discriminately validity in perinatal populations. STAI
scores >48 are predictive of having an anxiety disorder
diagnosis [54]. Knowledge of depression treatment options
is assessed using a knowledge questionnaire that includes
items regarding the effectiveness of various treatment op-
tions, as well as known possible adverse effects. Women
will be asked to estimate effectiveness of each presented
treatment option on a continuous scale from 0 to 100 %.
Content knowledge items are presented as “true” or
“false.” This tool is a modified version of a tool previously
created and validated by a member of our team in other
PDA evaluations (KM) [55]. Provider views about their
perceptions of the utility of the PDA for their patients are
also collected using a modified version of a provider satis-
faction tool for PDAs created for previous studies by
members of our team (KM) [55].
We also audio-record the first clinical interaction be-
tween each patient and her provider subsequent to
randomization (see Table 1). Audiotapes will be tran-
scribed verbatim and analyzed using qualitative methods.
This method was developed in conjunction with the teams
of family physicians and psychiatrists who will be seeing
the study patients. They will have the opportunity to re-
view the PDA and the research protocol prior to the start
of the study and can opt out of the audiotaping at any
time. Providers will provide clinical care to study partici-
pants in both groups. If providers learn from interactions
with women in the intervention (PDA) group, this could
Table 1 Study schedule for data collection measures and time points
Study variable Sample Measure Baseline clinic visit 4 weeks LT F/Ug
Eligibility All subjects Eligibility assessment Prior to enrollment
Non-participation Recruitment issues Prior to enrollment
Demographics Participant characteristicsc X
Mental health MINIc, d X
EPDSb, e and STAIb, f X X X
Decisional conflict Decisional Conflict Scaleb X X
Knowledge Knowledge Questionnaireb X X
Adherence Website use and Chart reviewa X X
Patient-provider Audiotaped clinic visitb X
Decision Health Service Questionnairec X X X
Participant views PDA only Acceptability Questionnairea X
Provider views Providers Provider Perspective Surveya Xh
aFeasibility; bEfficacy; cCovariate; dMini Neuropsychiatric Interview; eEdinburgh Postnatal Depression Scale; fState-Trait Anxiety Inventory; gLT F/U = long-term
follow-up: at 12 weeks postpartum (for women enrolled while pregnant) or 6 months after baseline assessment (for women enrolled while planning a pregnancy);
hCollected only after all other subject data collection is complete. PDA patient decision aid
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change interactions with all patients. If this positively im-
pacts decisional conflict for participants in the control
group, the observed effect size of the PDA intervention
could be reduced [56]. While cluster randomization (e.g.,
by site or by provider) could minimize such a bias, this
raises issues of feasibility, size, cost, as well as issues of sys-
tematic differences between study sites (or between pro-
viders) that could confound results. As such, the impact of
provider learning needs to be considered to inform the de-
sign of the future RCT. To assess for a possible impact of
provider learning, we will analyze the temporal trends in
decisional conflict scale outcomes over time in both
groups, and compare temporal trends in decisional con-
flict scale outcomes between PDA and control groups. If
decisional conflict outcomes in the control group are bet-
ter for participants enrolled later in the study, compared
to participants enrolled in the early part of the study, a
cluster-randomized design may be preferred in the future
RCT. Similar methods have been used to assess the im-
pact of provider learning over time in interventions in-
volving the use of new surgical skills and procedures [57].
Statistical methods
Means will be calculated to determine feasibility and com-
pliance estimates for recruitment rate, rates of non-
participation, completion rate of the PDA, number of
pages reviewed within active study phase, follow-up rates
at the various intervals, and so on. We will measure the
acceptability of the intervention using the Likert-type scale
responses from the participant and provider question-
naires, and will collate additional comments made by par-
ticipants or providers for consideration of modifications
to the content, layout or technical capacity of the PDA.
To compare decisional conflict between women receiving
the PDA to women receiving the comparison condition
we will use the intention-to-treat principle. Missing data
points will be excluded from the analysis, and individuals
with less than two DCS measurements will be treated as
lost to follow-up. An on-treatment analysis will also be
performed as a sensitivity analysis (for best possible per-
formance of the PDA). Means of the DCS scores of the
experimental and comparison groups at the primary end-
point (4-week follow-up) will be compared using a one-
way analysis of covariance (ANCOVA) model, where the
covariate will be baseline DCS score. This effect size will
be used to generate the sample size needed for the future
RCT. For other secondary outcomes, continuous mea-
sures will be compared between groups using t tests for
independent samples (or ANCOVA to account for base-
line scores) and dichotomous measures using chi-square
tests of association. Audiotaped participant-provider visits
will be transcribed verbatim and analyzed using inductive
thematic qualitative content analysis. The frequency, ex-
tensiveness and specificity of comments will guide data
categorization into recurrent themes. Themes will be al-
tered and refined through a recursive process from the
data to analyst-generated categorical and conceptual defi-
nitions. NVivo software will be used to facilitate compari-
sons between experimental and comparison groups.
Recruitment will continue for 1 year, and no analysis per-
formed until the last participant has completed final
follow-up.
Sample size
A review by Hertzog suggests a range of 20–40 partici-
pants to allow for sufficient variability in acceptability as-
sessment of an intervention [58]. The RLS program at
WCH is a specialty program that treats women experien-
cing mental health concerns related to the reproductive
life stages (including menstruation, pregnancy, postpar-
tum and menopause) and conducts approximately 40 con-
sultations per month for perinatal depression; of these
approximately 11 have moderate to severe depression in
pregnancy. Based on a previous study on decisional con-
flict [44], we estimate that six (approximately 50 %) will be
ineligible due to low decisional conflict, one will be ineli-
gible for another reason and three of the remaining five
(60 %) will agree to participate in the study. As such, re-
cruitment of 36 women could be achieved through this
clinic in 1 year. WCH also has a Family Practice clinic that
cares for approximately 350 pregnant women per year. Es-
timating an eligibility rate of 11 %, 39 would be eligible for
the study, so 24 (60 %) women could be recruited by this
site over a 1-year period. In total, this would allow for re-
cruitment of 50 participants over the course of 1 year. We
aim to recruit at least 25 participants to the intervention
group, allowing for 20 % loss to follow-up for a minimum
of 20 per group. Among women with mean DCS score =
30 (moderate-high) and SD 14.8 (based on pilot data), a
total sample size of 40 participants would allow us to de-
tect a 13-point difference in DCS scores (clinically signifi-
cant) between intervention and control groups with
probability (power) 0.8 (type 1 error rate or alpha = 0.05).
Safety monitoring
A committee consisting of the principal investigator (PI),
study co-investigators and the research assistant will hold
teleconferences as necessary to discuss study progress, in-
cluding participant recruitment, and unexpected issues. Be-
cause of the low-risk nature of this intervention, an
independent Data Safety Monitoring Board will not be de-
veloped. Safety will be assessed at all follow-up time points
and be routinely reviewed by the PI. Adverse events will be
recorded and serious adverse events immediately reported
(within 24 hours by telephone or fax) to the WCH REB for
consideration of further action (i.e., unblinding of interven-
tion, subject withdrawal, termination of study). Protocols
will be developed regarding specific criteria for termination
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during the active study phase that will include active
suicidal ideation, psychosis and acute pregnancy complica-
tions that might change the considerations required for
treatment decisions. If termination criteria are met, the par-
ticipant will be removed from the study and followed by
her physician. Participants who terminate early will form
part of the intention-to-treat analysis.
Confidentiality
Participant confidentiality will be maintained by using
an ID number (not related to name or date of birth) on
all documents. Information linking these ID numbers
with the subjects’ identity will be kept separate from the
research records. Computer-based data will be entered
into password-secured databases and paper files stored
in a secure location. Data will only be accessible to study
personnel. User profile and system data stored and
transmitted by the study website is secured both tech-
nically and by business practices in compliance with
Government of Canada privacy standards. Data will be
hosted entirely within Canada adhering to jurisdictional
compliance standards. Data will be stored after the end
of the study on a password-protected electronic archive
for the PI to access for 5 years. The approving REB will
be granted direct access to the study participants’ ori-
ginal medical records for verification of trial procedures
and/or data, without violating the confidentiality of the
participants, to the extent permitted by law and regula-
tions. In presenting results, participants’ identities will
be confidential.
Dissemination plan
The goal of this pilot study is to finalize the develop-
ment of a PDA for antidepressant use in pregnancy and
to determine whether it is feasible to conduct a larger
RCT to definitively evaluate the PDA. The goals of the
KT plan relevant to this are to: (1) inform future re-
search in terms of providing evidence to proceed to a
larger study of the efficacy of the PDA, and (2) generate
awareness and interest in both the research community
and in the public about the potential of the PDA. To
meet the first goal of the KT plan, potential partners for
a planned larger trial require engagement. Our multi-
disciplinary team has connections to centers throughout
Canada, the United States and the UK, and pending suc-
cess of the pilot study we will hold a trial-planning meet-
ing after data collection is complete to prepare for a
larger multi-site RCT to definitively evaluate the PDA.
To meet the second goal of the KT plan, practitioners,
the public, stakeholder groups and policy-makers are
target audiences. Specifically, the team has ongoing rela-
tionships with several community and public health
agencies and stakeholder groups that focus on perinatal
depression. We will share pilot study findings with these
key stakeholders, many of whom were instrumental in
the PDA development to date. These presentations are
integrated knowledge translation activities as they are bi-
directional in nature. Stakeholders will help inform us,
while at the same time serving to disseminate informa-
tion and generate interest and awareness about the po-
tential of the PDA as an intervention. Finally, to
promote the legitimacy of our findings, we will submit
results for peer-reviewed publication and present the re-
sults of the pilot study (once peer-reviewed) in at least
one national and international scientific conference.
Discussion
Depression complicates a large number of pregnancies,
more often than gestational diabetes, hypertension or
pre-eclampsia [1]. Furthermore, depression in pregnancy
poses a significant risk to both mother and developing
fetus, yet few women receive adequate care. Antidepres-
sant medication is often the most effective treatment op-
tion, but is associated with risks. This causes women to
struggle with decisions around their treatment options,
despite physician and informational support. PDAs are
interventions that reduce decisional conflict and en-
hance effective decision-making. To our knowledge,
there has been no other PDA for antidepressant use in
pregnancy that has been rigorously evaluated for efficacy
as an adjunct to clinical care.
The electronic nature of our tool is a major advantage
to our protocol and its scalability, because it means that:
(1) women will be able to access it privately and se-
curely, augmenting care particularly in areas where ac-
cess to specialists is scarce, (2) it will be feasible to
update the contained information on a regular basis to
keep up with the consistently changing literature in this
area, (3) it is easily adaptable and disseminated to other
settings. For example, we have developed a collaboration
with King’s College in the UK where the PDA is being
adapted to suit the context of mental health care in the
UK (i.e., different brand names of medication, etc.) and
where a pilot study in the Greater London Area has
been funded to pilot test the PDA in that setting.
There are some limitations to our pilot study method-
ology. We are restricting our sample to women who are
less than 30 weeks gestation to increase the likelihood
that the decision would be implemented during the
pregnancy. The disadvantage of this is that our results
may not be applicable to women in late pregnancy. Also,
because this is a pilot study, our results will not provide
us with conclusions about the efficacy of the PDA for
women making decisions about antidepressant use in
pregnancy, but rather, will help guide the development
of a larger study to focus on this matter.
Deciding whether or not to treat depression with antide-
pressants during pregnancy can be a complex decision for
Vigod et al. Trials  (2016) 17:110 Page 7 of 9
women to make, even with clinical care and guidance.
Our PDA recognizes that women must be able to assess
her own values of the risks and benefits of her treatment
options in order to make an informed and effective deci-
sion. This study will allow us to determine the feasibility
of our protocol for a larger, multi-site RCT in order to de-
termine the efficacy of a relatively simple, low-cost inter-
vention that has the potential to help a significant number
of women and unborn children.
Trial status
Enrollment for this study began 1 February 2015. At the
time of article submission we have enrolled 37 participants.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents* (DOCX 48 kb)
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